Earticle

초록

영어

As a representative new medicine of Korea which has advanced to the global market, `Supect`, the no tolerance and no side-effect medicine for chronic myelogenous leukemia developed by Ilyang Pharmaceutical Co., Ltd. may be mentioned above all without hesitation. 'Supect' which was introduced as a representative role model for R&D and commercialization of innovative new medicine at the 2015 BIO International Convention may be called a success model for development of innovative medicine and new market which wisely overcame domestic and foreign entry barrier of licensing. Showing will to develop new medicine, Government has kept supporting and, in the process, basic research infrastructure has matured much in the industry's research institutes and schools. As technology is built and research ability of companies grows, the outcome of new medicine development will accelerate more and more. Survey of progression stages of new medicine development made by each research institution shows that externally division of roles between institutions involved in new medicine development is necessary for each R&D stage over the whole period and internally technology transfer or cooperative research is imperative between universities and companies or research institutes and companies. Any company cannot secure the overall infrastructure and experiences of alliance and cooperation required for development of globally competitive new medicine in a short term. National support system which can induce more efficient R&D and formation of incubative environment for developing innovative new medicine are necessary. Development of new medicine is progressed as a multidisciplinary R&D over the whole period. Such open innovation strategies that are freely able to operate space-time transcending real-time win-win cooperation with outside institutions possessing technologies are being established as core strategies for developing new medicine. To prevent bottleneck phenomenon occurring when investment on new medicine research is connected to new medicine development, the open innovation system for new medicine development and commercialization in which industry, academics, research community and government can coexist and pursue co-prosperity should be well operated.

저자

• Jae Cheon Yeo [ 여재천 | Executive Director, Korea Drug Research Association ]

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국당과학회 학술대회

• 간기

  연간

• 수록기간

  2006~2022

• 십진분류

  KDC 517 DDC 614